BioCryst Pharmaceuticals (BCRX) Files $70M Mixed Securities Shelf
In a Form S-3 after the close on Friday, BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that it may, from time to time, offer $70 million worth of securities to the public. The securities include common stock, preferred stock, warrants and units, etc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.
Create E-mail AlertRelated Categories
Equity OfferingsStocks Mentioned
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
